11th Conference on Retroviruses and Opportunistic Infections


San Francisco, California - February 8 - 11, 2004

Print this Article


High HIV Incidence among Men Who Have Sex with Men Participating in an HIV Vaccine Efficacy Trial, United States, 1998-2002

Conf Retroviruses Opportunistic Infect. 2004 Feb 8-11;11th:Abstract No. 857

M Ackers*1, A Greenberg1, C Lin1, B Bartholow1, A Hirsch2, M Longhi2, and M Gurwith2
1CDC, Atlanta, GA, USA and 2VaxGen Inc., Brisbane, CA, USA

BACKGROUND: From June 1998 through October 1999, 4697 high-risk HIV-negative men who have sex with men (MSM) were enrolled at 56 U.S. clinical trial sites into the 36-month AIDSVAX B/B HIV vaccine efficacy trial. MSM were enrolled from 27 states, Washington, DC, and Puerto Rico. These trial data provide important information regarding current HIV seroincidence trends in this population.

METHODS: Demographic characteristics, sexual and drug risk behaviors, and HIV status were assessed and HIV risk reduction counseling was provided at baseline and at 6-month intervals. Since no overall vaccine efficacy was detected among MSM, we combined data from both vaccine and placebo arms of the trial. Incidence was calculated based on person-years of follow-up for MSM who initially tested negative for HIV and received at least one additional HIV test during the study period.

RESULTS: Overall, HIV incidence was 2.8/100 person-years (95%CI: 2.5 to 3.1). HIV incidence by subgroup was as follows:

Characteristic No. SC*/ No. MSM HIV inc/100
py**95% CI)
Year    
1998-99 78/4697 2.6
(2.0-3.2)
2000 135/4202 3.2
(2.7-3.8)
2001 101/3926 2.7
(2.2-3.3)
2002 22/3051 1.7
(1.1-2.6)
Race    
White 287/4012 2.8
(2.4-3.1)
Hispanic 22/319 2.9
(1.8-4.3)
African American 10/173 2.4
(1.1-4.4)
Asian 6/72 3.2
(1.2-6.8)
Age group (yrs.)    
18-30 117/1320 3.8
(3.1-4.6)
31-40 144/1888 2.9
(2.4-3.4)
41-50 61/1118 2.0
(1.5-2.6)
51-64 16/358 1.7
(.95-2.7)
Characteristic No. SC*/ No. MSM HIV inc/100
py**95% CI)
Geographic region    
Midwest 56/912 2.4
(1.8-3.1)
Northeast 60/873 2.6
(2.0-3.4)
South 105/1448 2.9
(2.4-3.5)
West 116/1409 3.2 (2.6-3.8)
STI diagnosis†    
Syphilis 4/30 5.1
(1.4-3.1)
Gonorrhea 29/279 3.8
(2.6-5.5)
Chlamydia 15/161 3.4
(1.9-5.6)
Drug use†
Amphetamine 106/901 4.5
(3.6-5.4)
Hallucinogen 70/603 4.0
(3.3-4.7)
Popper 211/2176 3.6
(3.1-4.1)

040208
857

Copyright © 2004 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed (AIDSLINE) from National Library of Medicine.